LIPOSORBER® Provides Hope When Drug Therapy Fails™
LIPOSORBER is an extracorporeal therapy that enables patients to attain the recommended therapeutic targets when diet and maximum drug therapies have failed or are not tolerated. LIPOSORBER is shown to acutely reduce harmful cholesterol agents: Low-Density Lipoprotein Cholesterol (LDL-C), Lipoprotein(a) [Lp(a)].1
Mary N. – Familial Hypercholesterolemia (FH) Patient Story
Cardiovascular Disease
Treatment with LIPOSORBER can help Familial Hypercholesterolemia (FH) patients reduce coronary events
by 72%.2*
Kidney Disease
Treatment with LIPOSORBER has enabled nearly 50% of steroid-resistant primary FSGS patients to attain complete or partial remission.3**
Locate a Treatment Center Near You
Are you a candidate for LIPOSORBER® Therapy?
LIPOSORBER is an FDA approved device that removes low-density lipoprotein cholesterol (LDL-C) and Lipoprotein(a) [Lp(a)] from the blood. Approximately 600,000 treatments have been performed worldwide on over 6,000 patients. Talk to your doctor about whether LIPOSORBER is right for you. Click below to take our quiz and discuss with your doctor.
References
- Kaneka Medical America LLC., 2022 LIPOSORBER® LA-15 SYSTEM Operator’s Manual No.1002en-R7.
- Mabuchi, H et al. “Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia.” Hokuriku-FH-LDL-Apheresis Study Group. The American journal of cardiology vol. 82,12 (1998): 1489-95. doi:10.1016/s0002-9149(98)00692-4.
- Muso, Eri et al. “Immediate therapeutic efficacy of low-density lipoprotein apheresis for drug-resistant nephrotic syndrome: evidence from the short-term results from the POLARIS Study.” Clinical and experimental nephrology vol. 19,3 (2015): 379-86. doi:10.1007/s10157-014-0996-8.
*Serum lipid levels and outcomes in each treatment group were compared after approximately 6 years.
**Based on study that took place over two (2) years.
